Sign inJoin waitlistJoin the waitlist

Nicholas Short

Associate Program Director · University of Texas M D Anderson Cancer Center

Credentials: · · · · ·

History

University of Texas M D Anderson Cancer Center
Present
Section of Developmental Therapeutics · University of Texas M D Anderson Cancer Center
Present
Leukemia · University of Texas M D Anderson Cancer Center
Present

Hematology and Medical Oncology
University of Texas M D Anderson Cancer Center
2014–2017
Internal Medicine
Brigham and Women's Hospital
2011–2014
Baylor College of Medicine
2007–2011

Research

Acute myeloid leukaemia
Review · The Lancet · 2018 · First of 3 authors · 641 citations
Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia: A Systematic Review and Meta-analysis
Systematic review or meta-analysis · JAMA Oncology · 2020 · First of 13 authors · 338 citations
Advances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges
Review · Cancer Discovery · 2020 · First of 7 authors · 297 citations

Hagop Kantarjian
294 papers
Elias Jabbour
279 papers
Tapan Kadia
234 papers
Naval Daver
198 papers
Courtney DiNardo
189 papers
Guillermo Garcia-Manero
185 papers
GB
Gautam Borthakur
162 papers
KS
Koji Sasaki
153 papers · 16 as a fellow
Ghayas Issa
139 papers · 7 as a fellow
Nitin Jain
137 papers
Marina Konopleva
136 papers
Musa Yilmaz
114 papers · 1 as a fellow

Grants

Advancing TGFβ-Resistant CAR-NK Cell Therapy for Acute Myeloid Leukemia
National Cancer Institute · R01
PI · $387.2K · University of Tx Md Anderson Can Ctr
2026–2031

Clinical trials

A Phase 1 Study Of FLAG Chemotherapy In Combination With Lisaftoclax And Pelcitoclax In Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia
Principal investigator · Withdrawn · Phase 1
M.D. Anderson Cancer Center
2026
A Phase I/II Study of CAR.70-Engineered IL15-Transduced Cord Blood-Derived NK Cells With TGF-beta Receptor 2 (TGFBR2) Knock Out in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Myeloid Malignancies
Principal investigator · Recruiting · Phase 1, Phase 2
M.D. Anderson Cancer Center
2025–2030
A Phase I Study of Decitabine, Lisaftoclax, and Olverembatinib in Patients With Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Myeloid Leukemia
Principal investigator · Recruiting · Phase 1
M.D. Anderson Cancer Center
2024–2029
Phase I/II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Principal investigator · Recruiting · Phase 1, Phase 2
M.D. Anderson Cancer Center
2024–2029